# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Edward W. Brooke (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML014-SYN
- Date: 2026-02-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Howard Bellamy, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week follow-up on tamoxifen; bone density results; medical oncology seen today. **S**

## History of present illness

Mr. Brooke returns four weeks after his first visit. He has taken tamoxifen 20 mg every day for fifteen weeks and keeps the bottle by his toothbrush. He has mild hot flashes two or three times a week, mostly at night, which do not stop him sleeping. He has had no leg swelling or pain, chest pain, or breathlessness, and no change in vision. The mastectomy scars are comfortable and he has full movement of the right shoulder, with no arm swelling. He had his DXA scan this morning and saw Dr. Cho of medical oncology, who has taken over his tamoxifen and sent a germline genetic test today. He starts vitamin D today for the low level found at the first visit. He walks most days. **S**

| Element | Detail |
|---|---|
| Tamoxifen | Fifteen weeks; no missed doses |
| Side effects | Mild night hot flashes; no clot symptoms or visual change |
| Surgical sites | Comfortable; full right shoulder movement; no arm swelling |
| Coordination | Medical oncology seen today; germline test sent |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fatigue, weight loss, or night sweats |
| Endocrine | Positive | Mild hot flashes at night |
| Cardiovascular | Negative | No chest pain or leg swelling or pain |
| Respiratory | Negative | No cough or breathlessness |
| Musculoskeletal | Negative | No bone pain; full shoulder movement |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |

6 systems reviewed. **S**

## Current medications

- Tamoxifen 20 mg oral tablet, one tablet by mouth once daily (adjuvant endocrine therapy, planned for at least five years) **S**
- Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 130/74 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 81.8 kg; BMI 24.4 kg/m². All vital signs are synthetic.

Femoral neck T-score (DXA): -1.2 (low); Lumbar spine T-score (DXA): -0.4; PHQ-2: 0. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Chest wall | Healed transverse mastectomy scars on both sides; no nodule or skin change |
| Lymph nodes | Right axillary scar healed; no axillary, supraclavicular, or cervical nodes on either side |
| Extremities | Upper arm circumference 31 cm on both sides; no calf swelling or tenderness |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Right breast cancer, stage IIA, after bilateral mastectomy and axillary dissection** (C50.121). No evidence of recurrence. Dr. Cho agrees that tamoxifen alone is the right adjuvant treatment and that chemotherapy and radiation would add little at his age with one involved node. **S**
   - Continue the plan from the consultation.
   - Germline result to be reviewed with the genetic counselor.
2. **Long-term tamoxifen; bone health** (Z79.810). Tolerating tamoxifen with mild hot flashes. DXA shows low bone mass at the femoral neck (T-score -1.2) and a normal spine (-0.4); vitamin D was 24 ng/mL. His ten-year fracture risk is below the treatment threshold, so no bone drug is needed. **S**
   - Cholecalciferol 1000 units daily, starting today.
   - Calcium from food, about 1200 mg a day; walking and light weights.
   - Recheck vitamin D in three months; repeat DXA in two years.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Cancer-related history and examination of both sides of the chest wall and both axillae | Every 3 to 6 months for 3 years | Completed today | No nodule, skin change, or nodes |
| Examination | Lymphedema assessment and risk-reduction counseling | Every visit after axillary surgery | Completed today | Arm circumferences equal at 31 cm; skin care and early reporting reviewed |
| Medication safety | Venous thromboembolism symptoms on tamoxifen | Every visit on tamoxifen | Completed today | No leg swelling or pain, chest pain, or breathlessness |
| Medication safety | Hot flashes on tamoxifen | Every visit on tamoxifen | Completed today | Mild, at night; no treatment needed. Paroxetine, fluoxetine, and bupropion are to be avoided because they block the activation of tamoxifen |
| Medication safety | Sexual side effects of tamoxifen (libido, erectile function) | Every visit on tamoxifen | Deferred | Not asked today, a deviation from the protocol; the visit was taken up by the bone density and consultation results. To be asked at the next visit |
| Medication safety | Adherence to tamoxifen | Every visit on tamoxifen | Completed today | No missed doses; pill bottle kept by his toothbrush |
| Survey | Distress and depression screen (PHQ-2) | Every visit | Completed today | PHQ-2 score 0 |
| Imaging | Bone density (DXA) | Baseline on hormone therapy, then every 2 years | Completed today | Femoral neck T-score -1.2 (low bone mass); lumbar spine -0.4 (normal) |
| Laboratory | 25-hydroxyvitamin D | At baseline, then three months after starting a supplement | Due | 24 ng/mL at the first visit; recheck in three months |
| Laboratory | Germline multigene panel testing | Once, for every man with breast cancer | Ordered | Blood sent today by medical oncology; genetic counseling before and after the result |
| Referral | Medical oncology | Once, then as the oncologist advises | Completed today | Seen today; recommendations in the consultation note |
| Imaging | Breast imaging (mammography) | Yearly only for a remaining breast after lumpectomy, or the other breast with a predisposing variant | Not indicated | Both breasts were removed; there is no breast tissue to image |
| Laboratory | Routine blood tests, tumor markers, and CT, bone scan, or PET | Not recommended without symptoms in stage I to III disease | Not indicated | No symptoms suggesting recurrence |
| Self-management | Physical activity | Every visit | Completed today | Walking most days; light weights added for bone health |

## Goal progress

- Take tamoxifen every day with side effects managed, aiming to continue for at least five years. In progress; target 2026-08-11. **S**
- Complete germline genetic testing with counseling, and give him written information for his relatives. In progress; target 2026-05-12. **S**
- Establish bone health on hormone therapy at his age: DXA, vitamin D of 30 ng/mL or more, and weight-bearing exercise. In progress; target 2026-05-12. **S**
- Give a written survivorship care plan with the surveillance schedule. In progress; target 2026-08-11. **S**

## Medication changes

- Started: Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**

## Guideline basis

- Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020), American Society of Clinical Oncology
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025), National Comprehensive Cancer Network
- Shapiro CL, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline (2019), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026), Aether Forge

## Follow-up

- Primary care review in three months with a vitamin D recheck. Genetic counseling appointment for the result. Medical oncology every six months. **S**
- Next scheduled visit 2026-05-12: three-month follow-up: germline result, tamoxifen side effects and adherence, vitamin D recheck. **S**
